Issue 5/2012

  • It's finally spring for EU biotechs

    In this issue:

    • Austrian efforts to implement a total national ban on GMOs
    • Finland's UPM invests €150m in biodiesel refinery
    • AstraZeneca to take over US gout drug specialist Ardea
    • SPECIAL: Contract Research – Opportunities for outsourcing
    • Cancer start-up Vivia Biotech secures Series B financing 
    • Gedeon Richter opens huge biologics manufacturing plant
    • Databases link cancer cell genomics to drug efficacy

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/5.html

Kurszettel

Alle Kurse

TOP

  • MOLOGEN7.65 EUR18.42%
  • BB BIOTECH150.50 EUR5.10%
  • CO.DON2.69 EUR4.26%

FLOP

  • 4SC0.80 EUR-8.05%
  • CYTOS0.16 CHF-5.88%
  • WILEX2.15 EUR-4.44%

TOP

  • BIOFRONTERA2.85 EUR27.2%
  • MOLOGEN7.65 EUR3.4%
  • HBM85.50 CHF3.1%

FLOP

  • PAION2.20 EUR-32.3%
  • 4SC0.80 EUR-29.8%
  • CYTOS0.16 CHF-23.8%

TOP

  • SANTHERA81.90 CHF2267.1%
  • CO.DON2.69 EUR195.6%
  • PAION2.20 EUR155.8%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.80 EUR-54.0%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 21.10.2014